Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 4

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 4
---
 Warrant Inducement Agreement dated March 16, 2025.

The Selling Securityholder may,
from time to time, sell, transfer or otherwise dispose of any or all of their common stock or interests in their common stock on any stock
exchange, market or trading facility on which the common stock is traded or in private transactions. These dispositions may be at fixed
prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
at the time of sale, or at negotiated prices. See “Plan of Distribution” in this prospectus for more
information. We will not receive any proceeds from the resale or other disposition of the common stock by the Selling Securityholder.
However, we will receive the proceeds of any cash exercise of the Inducement Warrants. See “Use of Proceeds”
beginning on page 27 and “Plan of Distribution” beginning on page 41 of this prospectus for more information.
The offering will settle delivery versus payment (“DVP”)/receipt versus payment (“RVP”). Accordingly, we and the
placement agent have not made any arrangements to place investor funds in an escrow account or trust account since the placement agent
will not receive investor funds in connection with the sale of the securities offered hereunder.

Our common stock is traded on
the Nasdaq Capital Market (“Nasdaq”) under the symbol “AEMD.” On August 18, 2025, the last reported sale price
of our common stock as reported on Nasdaq was $1.17 per share. We are a “smaller reporting company” as defined under the federal
securities laws and, under applicable Securities and Exchange Commission rules, we have elected to comply with certain reduced public
company reporting and disclosure requirements.

You should read this prospectus,
together with additional information described under the headings “Where You Can Find More Information,”
carefully before you invest in any of our securities.

We have agreed to pay the placement
agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. See “Plan of Distribution” section of this prospectus for more information regarding these arrangements. There is no minimum number of
shares of common stock or pre-funded warrants or minimum aggregate amount of proceeds that is a condition for this offering to close.
We may sell fewer than all of the shares of common stock and pre-funded warrants offered hereby, which may significantly reduce the amount
of